Our Impact Advocacy Neuroblastoma Australia raises funds for vital research and treatments, while uniting affected families and supporters in a common cause. Along with advocates in our community, we want to compel policymakers to prioritise neuroblastoma on the Government's agenda. At present, only 1.4% of Australian Government funding for cancer research goes to neuroblastoma. Childhood cancer, more broadly, receives only 10% of government funding. Of that childhood cancer amount, funding specifically for neuroblastoma research is just 16%. In 2022 the NHRMC invested $2.18 million in neuroblastoma research, which compares to $141 million in adult cancer research. This page details advocacy campaigns undertaken by Neuroblastoma Australia with our community members. Most of these will benefit greatly from public support and participation to amplify important lived experiences and messages so they are visible to those who have the power to make change happen. Senate Inquiry 2023 - Equitable Access to Diagnosis and Treatment On 14 June 2023, the Senate referred the following inquiry to the Senate Community Affairs Committee Equitable access to diagnosis and treatment for individuals with rare and less common cancers, including neuroendocrine cancer. You can find details here about this Inquiry. The Inquiry will review the experiences of those seeking treatment for rare and less common cancers, including barriers to screening and diagnosis due to cost and geographic location, and adequacy of support services post diagnosis. The full terms of reference can be found here. Neuroblastoma Australia Official Submission Working with community advocates and experts with formal submission experience, Neuroblastoma Australia drafted a submission letter to reflect the views of the charity regarding treatment accessibility. If you are a parent, guardian or close relative of a child with neuroblastoma, we welcome you to read our letter as follows: Neuroblastoma Australia Submission to Senate Submissions are now closed. We will provide relevant updates on the Senate's findings as they arise.